La Jolla Pharmaceutical Co.
| Nasdaq: LJPC
La Jolla Pharmaceutical Co. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics intended to significantly improve outcomes in patients with life-threatening diseases. It focuses on three product candidates: GCS-100, LJPC-501 and LJPC-401. The GCS-100 targets the protein galectin-3, which, when overproduced by the human body, has been associated with chronic organ failure and cancer. The LJPC-501 is a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome. The LJPC-401 product will be evaluated for the treatment of iron disorders. The company also plan to continue to evaluate other opportunities for potential product candidates for the treatment of unmet medical needs. The company was founded in 1989 and is headquartered in San Diego, CA.